About Imbio
Imbio is a company based in Minneapolis (United States) founded in 2005 was acquired by 4DMedical in December 2023. Imbio has raised $2.58 million across 10 funding rounds from investors including HHS, 4DMedical and Invenshure. Imbio offers products and services including Lung Density Analysis, Functional Lung Texture Analysis, Pulmonary Hypertension Assessment, Airway Analysis, and Coronary Calcification. Imbio operates in a competitive market with competitors including ArtiQ, Sime Dx, FibroNest, Echoliv and SonmolTech, among others.
- Headquarter Minneapolis, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Imbio, Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Imbio
Imbio offers a comprehensive portfolio of products and services, including Lung Density Analysis, Functional Lung Texture Analysis, Pulmonary Hypertension Assessment, Airway Analysis, and Coronary Calcification.
AI software for quantifying lung density in medical images.
AI tool for assessing lung texture and function patterns.
Software for evaluating hypertension in pulmonary arteries.
AI system for analyzing airway structures in images.
AI tool for detecting calcification in coronary arteries.
People of Imbio
Unlock access to complete
Unlock access to complete
Funding Insights of Imbio
Imbio has successfully raised a total of $2.58M across 10 strategic funding rounds. The most recent funding activity was a Grant round of $249.01 thousand completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Imbio
Imbio has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, 4DMedical and Invenshure.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Invenshure is focused on building companies from institutional IP.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Manufacturer of respiratory imaging and ventilation analysis equipment
|
Locked | Locked | Locked |
Investor details for Imbio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Imbio
Investment portfolio details for Imbio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Imbio
Detailed financials for Imbio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Imbio Comparisons
Peer comparison for Imbio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Imbio
Imbio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArtiQ, Sime Dx, FibroNest, Echoliv and SonmolTech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-powered software to optimize clinical trials and enhance diagnostic processes
|
|
| Locked | Locked | Locked |
Point-of-care digital diagnostics are developed and provided by Sime Dx.
|
|
| Locked | Locked | Locked |
AI tools for quantifying fibrosis and inflammation in medical images for drug development.
|
|
| Locked | Locked | Locked |
AI-based tool for liver cancer diagnosis is provided to providers.
|
|
| Locked | Locked | Locked |
SonmolTech is engaged in developing respiratory care technology solutions.
|
Detailed competitors of Imbio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Imbio
Complete news archive for Imbio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Imbio
Imbio was founded in 2005 and raised its 1st funding round 8 years after it was founded.
Imbio is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
Imbio is a funded company, having raised a total of $2.58M across 10 funding rounds to date.
Imbio is a medical imaging company that develops clinical decision-support solutions using big data and medical image analysis. The companys current offerings are focused on 3D visualization and automated analysis of respiratory system images derived from CT scans. These include CE marked Functional Lung Density Analysis (fLDA) tests (a fully-automated image analysis system that provides a complete mapping of normal lung, air trapping, and areas of persistent low density in a combined image to help visualize the components of COPD), and LDA for Inspiration Analysis for Lung Screening and basic COPD assessment (test to identify and quantify emphysema), and Lung Texture Analysis using High Resolution CT images (for visualization, detection and quantification of lung fibrosis). The company has also developed investigationalresearch tools for airway analysis (analysis of airway remodelling, a characteristic feature of many lung diseases), computer-aided nodule assessment and risk yield (also called CANARY, this is a non-invasive imaging technique licensed from the Mayo Clinic, to risk stratify adenocarcinoma) and RVLV analysis to predict short-term mortality and adverse clinical events in patients with acute pulmonary embolism.
Imbio offers Lung Density Analysis, Functional Lung Texture Analysis, Pulmonary Hypertension Assessment, Airway Analysis, and Coronary Calcification.
Imbio has 3 investors. Key investors include HHS, 4DMedical, and Invenshure.